Last reviewed · How we verify
ATL administration
At a glance
| Generic name | ATL administration |
|---|---|
| Sponsor | Lukas Biomedical Inc. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Contribution of Optical Coherence Tomography in the Endovascular Treatment of Femoral Occlusions (NA)
- Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma (PHASE1)
- A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3) (PHASE1, PHASE2)
- Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma (PHASE2)
- Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL) (PHASE2)
- Diagnostic of Various Ototoxicity Induced by Cancer Treatment
- A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma (PHASE2)
- SEEG Guided RF-TC v.s. ATL for mTLE With HS (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ATL administration CI brief — competitive landscape report
- ATL administration updates RSS · CI watch RSS
- Lukas Biomedical Inc. portfolio CI